Cadence Neuroscience Receives FDA IDE Approval to Begin Multicenter Study of its Biomarker Targeted Stimulation Therapy for Focal Drug-Resistant Epilepsy
FDA authorization enables prospective BTSEE study in 45 pediatric and adult patients at up to 10 U.S. comprehensive epilepsy centers REDMOND, Wash., Oct. 14, 2026 /PRNewswire-PRWeb/ -- Cadence Neuroscience, a clinical-stage company developing a biomarker-guided platform for personalized...